Name: Lytenava (bevacizumab-vikg) in Neovascular age-related macular degeneration: Expected outcomes of therapy
Published: 2026-09-28T12:24:10-04:00

Product information and disease description Place of product in therapy Approaches to treatment

Expected outcomes of therapy

3 evidence topics · 2 sources

Vision stabilization and improvement with anti-VEGF therapy

“Anti-VEGF treatment improves vision in about one third (1 out of 3) people who take it.” (opens the source at this quote in a new tab)
“For a vast majority (9 out of 10), it at least stabilizes vision.” (opens the source at this quote in a new tab)

Contrast with untreated natural history

“ranibizumab not only prevented loss of vision in nAMD treatment-naïve patients (the natural history for these patients), but also, and for the first time ever in this disease, that their vision could recover, as shown by the 7.2 letters gained on average in the ranibizumab 0.5 mg dose group (the dose subsequently marketed) versus an average loss of 10.4 letters by the sham group.” (opens the source at this quote in a new tab)

Persistence of fibrotic scarring as a limit on outcomes

“long-term studies show that smaller and less severe fibrotic scars are not uncommon and develop over time despite optimal treatment.” (opens the source at this quote in a new tab)